SPOTLIGHT: Merck posts $1.6 billion loss

Merck reported a whopping $1.6 billion loss for the fourth quarter, mostly because of massive accounting charges related to its $4.85 billion Vioxx settlement. During the same period last year, Merck posted a $473.9 million profit. Meanwhile, some Florida patients left out of the Vioxx deal now want in. Report | Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.